NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
Refractory Metastatic Colorectal Cancer
DRUG: NKG2D CAR-NK
Dose-Limiting Toxicity#DLT#, Safety, 28 days|Maximal Tolerable Dose#MTD#, tolerability evaluation, 28 days
Antitumor efficacy-Duration of response (DOR), The period from the first evaluation of complete response ( CR) or partial response (PR) to the first evaluation of progressive disease (PD)or death of any cause., 52 weeks|Antitumor efficacy-Objective response rate (ORR), The number of cases in which tumor size is reduced to partial response (PR) or complete response (CR) / the total number of evaluable cases (%)., 52 weeks|Antitumor efficacy-Overall survival (OS), The period from the first study treatment to any cause of death, 52 weeks
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation.